Show simple item record

dc.contributor.authorXi, Song
dc.contributor.authorZhao, Ming
dc.contributor.authorWang, Si
dc.contributor.authorMa, Ling
dc.contributor.authorWang, Shensen
dc.contributor.authorCong, Xianling
dc.contributor.authorGjerset, Ruth A
dc.contributor.authorFitzgerald, Rebecca C
dc.contributor.authorHuang, Yinghui
dc.date.accessioned2018-11-01T14:03:05Z
dc.date.available2018-11-01T14:03:05Z
dc.date.issued2017
dc.identifier.issn1837-9664
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/284509
dc.description.abstractInternal ribosome entry sites (IRES elements) have attracted interest in cancer gene therapy because they can be used in the design of gene transfer vectors that provide bicistronic co-expression of two transgene products under the control of a single promoter. Unlike cellular translation of most mRNAs, a process that requires a post-translational 5' modification of the mRNA known as the cap structure, IRES-mediated translation is independent of the cap structure. The cellular conditions that may intervene to modulate IRES-mediated, cap-independent versus cap-dependent translation, however, remain poorly understood, although they could be critical to the choice of gene transfer vectors. Here we have compared the effects of the p14ARF (Alternate Reading Frame) tumor suppressor, a translational suppressor frequently overexpressed in cancer, on cap-dependent translation versus cap-independent translation from the EMCV viral IRES often used in bicistronic gene transfer vectors. We find that ectopic overexpression of p14ARF suppresses endogenous and ectopic cap-dependent protein translation, consistent with other studies. However, p14ARF has little or no effect on transgene translation initiated within an IRES element. This suggests that transgenes placed downstream of an IRES element will retain efficient translation of their gene products in the presence of high levels of ectopic or endogenous p14ARF, a finding that could be particularly relevant to therapeutic gene therapy strategies for cancer.
dc.format.mediumElectronic-eCollection
dc.languageeng
dc.publisherIvyspring International Publisher
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.titleIRES-Mediated Protein Translation Overcomes Suppression by the p14ARF Tumor Suppressor Protein.
dc.typeArticle
prism.endingPage1088
prism.issueIdentifier6
prism.publicationDate2017
prism.publicationNameJ Cancer
prism.startingPage1082
prism.volume8
dc.identifier.doi10.17863/CAM.31884
dcterms.dateAccepted2017-03-06
rioxxterms.versionofrecord10.7150/jca.17457
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc/4.0/
rioxxterms.licenseref.startdate2017-01
dc.contributor.orcidFitzgerald, Rebecca [0000-0002-3434-3568]
dc.identifier.eissn1837-9664
rioxxterms.typeJournal Article/Review
pubs.funder-project-idCambridge University Hospitals NHS Foundation Trust (CUH) (3819-1516-08)
pubs.funder-project-idMRC (unknown)
pubs.funder-project-idMedical Research Council (MC_UU_12022/2)
cam.issuedOnline2017-04-09


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial 4.0 International